[{"id":"79f91b60-669d-47f6-83fb-b95eccd77343","acronym":"NIVOFGFR2","url":"https://clinicaltrials.gov/study/NCT05859477","created_at":"2023-05-16T17:06:20.563Z","updated_at":"2024-07-02T16:35:24.858Z","phase":"Phase 2","brief_title":"Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer","source_id_and_acronym":"NCT05859477 - NIVOFGFR2","lead_sponsor":"Kidney Cancer Research Bureau","biomarkers":" HER-2 • PD-L1 • FGFR2","pipe":" | ","alterations":" HER-2 negative • FGFR2 amplification • FGFR2 overexpression • FGFR2 expression","tags":["HER-2 • PD-L1 • FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • FGFR2 amplification • FGFR2 overexpression • FGFR2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • capecitabine • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 06/05/2022","start_date":" 06/05/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-01"},{"id":"10546027-b8fd-4d19-9e12-032fc4a20162","acronym":"","url":"https://clinicaltrials.gov/study/NCT02491840","created_at":"2021-01-18T12:00:42.960Z","updated_at":"2024-07-02T16:35:40.221Z","phase":"","brief_title":"Biomoleculars Markers of Sensitivity to Pre- and Post-operative Chemotherapy of Gastric and Cardia Adenocarcinomas: a Pilot Study","source_id_and_acronym":"NCT02491840","lead_sponsor":"University Hospital, Strasbourg, France","biomarkers":" HER-2 • FGFR2","pipe":" | ","alterations":" HER-2 expression • MET expression • FGFR2 expression • FGFR2b expression","tags":["HER-2 • FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • MET expression • FGFR2 expression • FGFR2b expression"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 07/01/2029","primary_completion_date":" 07/01/2029","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2023-08-11"},{"id":"d4d894ac-2658-4499-8ad7-5be03852e67a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05173142","created_at":"2021-12-29T13:53:45.797Z","updated_at":"2025-02-25T14:52:10.343Z","phase":"Phase 1/2","brief_title":"HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors","source_id_and_acronym":"NCT05173142","lead_sponsor":"Hutchison Medipharma Limited","biomarkers":" FGFR","pipe":" | ","alterations":" PD-L1 expression • FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR2 overexpression • FGFR2 expression • FGFR2 translocation","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR2 overexpression • FGFR2 expression • FGFR2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • docetaxel • Loqtorzi (toripalimab-tpzi) • Tevimbra (tislelizumab-jsgr) • fanregratinib (HMPL-453)"],"overall_status":"Recruiting","enrollment":" Enrollment 141","initiation":"Initiation: 01/22/2022","start_date":" 01/22/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2022-03-08"},{"id":"5ac6cf9e-efcf-436f-8803-ff8e9e904ab6","acronym":"RPT835GC1B","url":"https://clinicaltrials.gov/study/NCT04071184","created_at":"2021-01-18T19:55:52.106Z","updated_at":"2024-07-02T16:36:55.182Z","phase":"Phase 1b","brief_title":"Study of Alofanib in Patients With Metastatic Gastric Cancer","source_id_and_acronym":"NCT04071184 - RPT835GC1B","lead_sponsor":"Russian Pharmaceutical Technologies","biomarkers":" FGFR2 • FRS2","pipe":" | ","alterations":" FGFR2 fusion • FGFR2 amplification • FGFR2 overexpression • FGFR2 expression","tags":["FGFR2 • FRS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion • FGFR2 amplification • FGFR2 overexpression • FGFR2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alofanib (RPT835)"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 05/26/2019","start_date":" 05/26/2019","primary_txt":" Primary completion: 10/01/2020","primary_completion_date":" 10/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2019-09-26"},{"id":"434f2313-9f1f-4287-82bb-2e00944ce448","acronym":"","url":"https://clinicaltrials.gov/study/NCT01881217","created_at":"2021-01-18T08:26:02.192Z","updated_at":"2025-02-25T17:06:51.733Z","phase":"Phase 1","brief_title":"First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors","source_id_and_acronym":"NCT01881217","lead_sponsor":"Bayer","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 expression • FGFR2b expression","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 expression • FGFR2b expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aprutumab (BAY 1179470)"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 06/28/2013","start_date":" 06/28/2013","primary_txt":" Primary completion: 03/18/2016","primary_completion_date":" 03/18/2016","study_txt":" Completion: 08/16/2016","study_completion_date":" 08/16/2016","last_update_posted":"2017-09-14"}]